Ann: September 2017 Quarterly Update and Appendix 4C, page-9

Here is the likely explanation as to why Senseras figures (excluding nanotron ) reflected what they were in the 3rd qtr:

As you know Sensera is looking at getting their two anchor clients into the commercial manufacturing stage by the end of this year, remember they have been doing prototype work for 12months. The medtech anchor client operating in the cardiovascular space will most likely be the first one into commercial manufacturing and quite possibly prototype work for this client slowed down in preparation for commercial manufacturing....

I certainly wouldn't be viewing that as a negative I would be viewing it as progress....

Just think about it, in a couple of qtrs time the revenues will be many multiples of what was shown in the 3rd qtr for Sensera....

cheers